StockNews.AI
EW
StockNews.AI
13 days

JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition

1. FTC moved to block Edwards Lifesciences' acquisition of JenaValve. 2. JenaValve disagrees with FTC and plans to defend the acquisition legally. 3. The acquisition aims to aid patients with aortic regurgitation and stenosis. 4. JenaValve's Trilogy THV System offers dual-disease treatment but is investigational in the U.S. 5. The case's outcome may significantly impact Edwards' market position.

4m saved
Insight
Article

FAQ

Why Bearish?

The FTC's intervention may delay or cancel the acquisition, affecting Edwards' growth strategy.

How important is it?

The acquisition blockage could hinder EDW's growth prospects, creating investor concern.

Why Short Term?

Legal challenges will unfold quickly, influencing investors' sentiment and stock price.

Related Companies

EDWJNVA
August 06, 2025 14:17 ET  | Source: JenaValve Technology, Inc. IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company’s proposed acquisition by Edwards Lifesciences. JenaValve respectfully disagrees with the FTC's decision and remains committed to completing the acquisition. JenaValve remains confident in both its rationale for the transaction and the value it will bring to the hundreds of thousands of patients suffering from aortic regurgitation. JenaValve intends to join Edwards to defend this case in court to complete the acquisition. About JenaValveJenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative THV solutions for the treatment of patients suffering from heart valve disease. The Company's Trilogy THV System is a TAVR system designed to treat patients with symptomatic, severe AR, and symptomatic, severe aortic stenosis who are at high surgical risk. The Trilogy THV System received CE Mark approval, providing European physicians with the first TAVR device with true dual-disease treatment capabilities. In the US, the Trilogy THV System is limited to investigational use only. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, Rosetta Capital, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI Partners, Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. Additional information is available at www.jenavalve.com. JenaValve Contact:Daniel Sundsun@jenavalve.com

Related News